PRESS RELEASES

Year
November 27 | 2023
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 13 | 2023
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 03 | 2023
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 01 | 2023
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
October 18 | 2023
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
August 30 | 2023
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 11 | 2023
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
June 07 | 2023
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
May 25 | 2023
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 11 | 2023
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 03 | 2023
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03 | 2023
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
April 26 | 2023
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
March 29 | 2023
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 14 | 2023
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
February 07 | 2023
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
January 03 | 2023
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference